GoodRx (GDRX) Projected to Post Quarterly Earnings on Thursday

GoodRx (NASDAQ:GDRX - Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of $0.10 per share and revenue of $199.73 million for the quarter. Investors interested in participating in the company's conference call can do so using this link.

GoodRx Stock Down 0.5 %

Shares of GDRX traded down $0.03 on Friday, hitting $4.84. 578,584 shares of the stock traded hands, compared to its average volume of 1,071,387. The company has a market capitalization of $1.84 billion, a PE ratio of -161.17, a P/E/G ratio of 2.60 and a beta of 1.28. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The business has a 50 day simple moving average of $4.67 and a 200 day simple moving average of $5.87. GoodRx has a one year low of $4.09 and a one year high of $9.26.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on GDRX. Barclays dropped their target price on shares of GoodRx from $10.00 to $6.00 and set an "overweight" rating on the stock in a report on Monday, November 11th. Mizuho began coverage on shares of GoodRx in a report on Wednesday, December 4th. They issued a "neutral" rating and a $5.00 target price on the stock. Morgan Stanley dropped their target price on shares of GoodRx from $7.00 to $6.00 and set an "equal weight" rating on the stock in a report on Tuesday, December 17th. KeyCorp dropped their target price on shares of GoodRx from $7.00 to $6.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Finally, Citigroup dropped their target price on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a report on Friday, January 10th. Five research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, GoodRx has a consensus rating of "Moderate Buy" and an average target price of $8.38.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.